CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Sex Differences in Instantaneous Wave-Free Ratio or Fractional Flow Reserve–Guided Revascularization Strategy Comparison of Safety and Periprocedural Complications of Transfemoral Aortic Valve Replacement Under Local Anaesthesia: Minimalist Versus Complete Heart Team Contemporary Approach to Coronary Bifurcation Lesion Treatment Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial The multiple causes and treatments of heart failure: focus on genetic and molecular mechanisms and non-pharmacological interventions

Original Research2021 Jan 12;S0828-282X(21)00005-2.

JOURNAL:Can J Cardiol. Article Link

When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease

E O'Meara, S Verma. Keywords: SGLT2 inhibitors; heart failure; chronic kidney disease

Full Text PDF